---
title: "Fuan Pharmaceutical (Group) Co.,Ltd. (300194.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/300194.SZ.md"
symbol: "300194.SZ"
name: "Fuan Pharmaceutical (Group) Co.,Ltd."
industry: "Pharmaceuticals"
datetime: "2026-05-20T04:34:49.041Z"
locales:
  - [en](https://longbridge.com/en/quote/300194.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/300194.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/300194.SZ.md)
---

# Fuan Pharmaceutical (Group) Co.,Ltd. (300194.SZ)

## Company Overview

Fuan Pharmaceutical (Group) Co., Ltd., together with its subsidiaries, research and develops, produces, and sells chemical drugs in the People's Republic of China. It offers APIs; intermediates; and FFPs, such as anti-tumor, generic drugs, antibiotics and oral, as well as freeze-drying preparation for injection. The company was formerly known as Chongqing Fuan Pharmaceutical (Group) Co., Ltd. and changed its name to Fuan Pharmaceutical (Group) Co., Ltd.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.fapharm.com](https://www.fapharm.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:08.000Z

**Overall: D (0.61)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 195 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -18.13% |  |
| Net Profit YoY | -72.23% |  |
| P/B Ratio | 1.07 |  |
| Dividend Ratio | 1.76% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 4718647949.54 |  |
| Revenue | 1676503513.14 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 0.00% | D |
| Profit Margin | 0.00% | D |
| Gross Margin | 40.58% | B |
| Revenue YoY | -18.13% | E |
| Net Profit YoY | -72.23% | E |
| Total Assets YoY | -7.34% | E |
| Net Assets YoY | -0.50% | D |
| Cash Flow Margin | 588.36% | A |
| OCF YoY | -18.13% | E |
| Turnover | 0.00 | E |
| Gearing Ratio | 21.44% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Fuan Pharmaceutical (Group) Co.,Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-18.13%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-72.23%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.07",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "1.76%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "4718647949.54",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "1676503513.14",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "40.58%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "-18.13%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-72.23%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "-7.34%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-0.50%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "588.36%",
          "rating": "A"
        },
        {
          "name": "OCF YoY",
          "value": "-18.13%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.00",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "21.44%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 75.89 | 128/215 | 37.63 | 34.25 | 24.49 |
| PB | 1.08 | 11/215 | 1.23 | 1.18 | 1.13 |
| PS (TTM) | 2.84 | 68/215 | 3.12 | 2.91 | 2.69 |
| Dividend Yield | 1.75% | 76/215 | 1.64% | 1.55% | 1.14% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/300194.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/300194.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/300194.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/300194.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**